Crucell N.V.

Type	Public (Euronext: CRXL, NASDAQ: CRXL)
Founded	2000
Headquarters	Leiden, Netherlands
Key people	Ronald Brus (CEO), Jan Pieter Oosterveld (Chairman of the supervisory board)
Industry	Biotechnology
Products	Vaccines and antibodies
Revenue	€267.2 million (2008)[1]
Operating income	▲ €7.9 million (2008)[1]
Net income	▲ €14.6 million (2008)[1]
Employees	1,130 (2008)[1]
Website	www.crucell.com

Crucell is a biotechnology company specializing in vaccines and antibodies. Its headquarters are located in Leiden, The Netherlands. Crucell shares are listed on the Euronext Amsterdam exchange and are part of the AMX index.

Contents 1 History 2 Vaccine products 2.1 Paediatric 2.2 Travel and endemic 2.3 Respiratory 3 References 4 External links

[edit] History

In 1993 Introgene was founded, which is Crucell’s predecessor. The company formed a partnership with Genzyme to collaborate on its vector technology and viral-based products. In 1999 the company founded Galapagos Genomics as a joint venture together with Tibotec. In 2000 IntroGene acquired U-Bisys to form Crucell.

In 2006, Crucell and Swiss Berna Biotech; Swedish SBL Vaccines and US-based Berna Products joined forces to become the sixth largest vaccine company worldwide, with their own clinical programs.

On 7 January 2009 Crucell released a press release saying Crucell and Wyeth were in discussion on a merger of the two companies. On 26 January 2009 Crucell released another press release saying the discussions on a combination of Crucell and Wyeth was discontinued due to Pfizer's acquisition of Wyeth.

On 28 September 2009 Johnson & Johnson bought 18% stake in Crucell for €302 milion in order to collaborate on the development of a flu vaccine.^[2]

[edit] Vaccine products

[edit] Paediatric

• Quinvaxem
• Hepavax-Gene
• MoRu-Viraten
• Epaxal-Junior

[edit] Travel and endemic

• Epaxal
• Vivotif
• Dukoral

[edit] Respiratory

• Inflexal V

[edit] References

1. ^ ^{a b c d} "Annual Report 2008". Crucell. http://hugin.info/132631/R/1312469/304318.pdf. Retrieved 2009-09-28. 
2. ^ Gray-Block, Aaron (28 September 2009). "Johnson & Johnson buys 18 pct stake in Crucell". Reuters. http://www.reuters.com/article/rbssPharmaceuticals%20-%20Generic%20&%20Specialty/idUSLS21205620090928. Retrieved 28 September 2009. 

[edit] External links

• Official website

v • d • e AMX companies of the Netherlands Aalberts Industries · AMG · Arcadis · ASM International · BinckBank · Crucell · CSM · Draka Holding · Eurocommercial Properties · Heijmans · Imtech · Logica · Mediq · Nutreco · Océ · Ordina · Prologis European Properties · Smit International · SNS Reaal · Ten Cate · USG People · VastNed Retail · Vopak · Wavin · Wessanen

This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. v • d • e